PURPOSE: To determine the role of gene-environmental interactions between the Class I and Class II HLA alleles and the humoral anti-Epstein-Barr Virus (EBV) responses in the development of brain injury and clinical disability in multiple sclerosis (MS) patients. METHODS: A total of 93 MS patients (62 females; 31 males) and 122 healthy controls underwent HLA typing and testing for antibodies against EBV. The MS patients underwent brain MRI and quantitative measurements of T1- and T2-lesion volumes (LVs) and brain parenchymal fraction (BPF) were obtained. There were 54 MS cases that underwent MRI and EBV-antibody assessments at the 3-year follow-up. The anti-EBV panel included measurements of the levels of anti-EBV early antigen (EA) IgG, anti-EBV nuclear antigen (EBNA) IgG and anti-EBV viral capsid antigen (VCA) IgM and anti-EBV VCA IgG. The relationships between HLA alleles, anti-EBV antibody levels, MRI and clinical parameters were assessed in regression analysis. RESULTS: The presence of HLA B7 was associated with increased T1-LV and trends indicating increased anti-EBV VCA IgG levels, higher disability (EDSS) and more destructive MRI parameters (increased T2-LV and decreased BPF). The presence of HLA A2 was associated with lower EDSS and a trend toward decreased anti-EBV VCA IgG levels; the associations with MRI variables were not significant. The HLA B7-A2 haplotype was significantly associated with higher T2-LV and T1-LV and a trend toward lower BPF was observed. CONCLUSIONS: Our data suggest that gene-environment interactions between specific HLA Class I loci and EBV exposure are associated with MRI markers of lesion injury and brain atrophy in MS patients.
PURPOSE: To determine the role of gene-environmental interactions between the Class I and Class II HLA alleles and the humoral anti-Epstein-Barr Virus (EBV) responses in the development of brain injury and clinical disability in multiple sclerosis (MS) patients. METHODS: A total of 93 MSpatients (62 females; 31 males) and 122 healthy controls underwent HLA typing and testing for antibodies against EBV. The MSpatients underwent brain MRI and quantitative measurements of T1- and T2-lesion volumes (LVs) and brain parenchymal fraction (BPF) were obtained. There were 54 MS cases that underwent MRI and EBV-antibody assessments at the 3-year follow-up. The anti-EBV panel included measurements of the levels of anti-EBV early antigen (EA) IgG, anti-EBV nuclear antigen (EBNA) IgG and anti-EBV viral capsid antigen (VCA) IgM and anti-EBV VCA IgG. The relationships between HLA alleles, anti-EBV antibody levels, MRI and clinical parameters were assessed in regression analysis. RESULTS: The presence of HLA B7 was associated with increased T1-LV and trends indicating increased anti-EBV VCA IgG levels, higher disability (EDSS) and more destructive MRI parameters (increased T2-LV and decreased BPF). The presence of HLA A2 was associated with lower EDSS and a trend toward decreased anti-EBV VCA IgG levels; the associations with MRI variables were not significant. The HLA B7-A2 haplotype was significantly associated with higher T2-LV and T1-LV and a trend toward lower BPF was observed. CONCLUSIONS: Our data suggest that gene-environment interactions between specific HLA Class I loci and EBV exposure are associated with MRI markers of lesion injury and brain atrophy in MSpatients.
Authors: Jan D Lünemann; Mar Tintoré; Brady Messmer; Till Strowig; Alex Rovira; Héctor Perkal; Estrella Caballero; Christian Münz; Xavier Montalban; Manuel Comabella Journal: Ann Neurol Date: 2010-02 Impact factor: 10.422
Authors: B C Healy; M Liguori; D Tran; T Chitnis; B Glanz; C Wolfish; S Gauthier; G Buckle; M Houtchens; L Stazzone; S Khoury; R Hartzmann; M Fernandez-Vina; D A Hafler; H L Weiner; C R G Guttmann; P L De Jager Journal: Neurology Date: 2010-08-17 Impact factor: 9.910
Authors: René M Gieß; Catherina Pfuhl; Janina R Behrens; Ludwig Rasche; Erik Freitag; Nima Khalighy; Carolin Otto; Jens Wuerfel; Alexander U Brandt; Jörg Hofmann; Bettina Eberspächer; Judith Bellmann-Strobl; Friedemann Paul; Klemens Ruprecht Journal: PLoS One Date: 2017-04-07 Impact factor: 3.240
Authors: Dana Horakova; Robert Zivadinov; Bianca Weinstock-Guttman; Eva Havrdova; Jun Qu; Miriam Tamaño-Blanco; Darlene Badgett; Michaela Tyblova; Niels Bergsland; Sara Hussein; Laura Willis; Jan Krasensky; Manuela Vaneckova; Zdenek Seidl; Petra Lelkova; Michael G Dwyer; Ming Zhang; Haoying Yu; Xiaotao Duan; Tomas Kalincik; Murali Ramanathan Journal: PLoS One Date: 2013-01-08 Impact factor: 3.240